CBClemens Bos

Clemens Bos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Clemens Bos has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost-utility of focused ultrasound compared to radiotherapy for Dutch patients with uncomplicated non-spinal bone metastases

    by Julia Simões Corrêa Galendi, Ingrid Nijholt, Renée Hovenier, Jorik Slotman, Erik Phernambucq, Stephanie Stock, Clemens Bos, Manon Braat, Helena Verkooijen, Martijn Boomsma, et al.

    Introduction: Non-randomized clinical trial has shown that Magnetic Resonance guided High-intensity focused ultrasound (MR-HIFU) leads to faster pain relief compared to the current standard of care External Beam Radiotherapy (EBRT). Objective: To evaluate the cost-utility of ’early MR-HIFU’ (with optional EBRT afterwards) or ‘delayed MR-HIFU’ (i.e., MR-HIFU after failed EBRT) versus EBRT (with optional re-irradiation with EBRT) from the societal perspective in the Netherlands Methods: A lifelong patient-level simulation model was developed. After a treatment with either MR-HIFU or EBRT, a patient could have: (i) complete pain relief, (ii) partial pain relief, (iii) persistent pain and (iv) death. We also accounted for the event of a pathological fracture. Model outputs were costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICER). The net monetary benefit was calculated considering the willingness-to-pay threshold of €80,000 per QALY gained, adjusted by the Dutch disease severity index. Deterministic and probabilistic sensitivity analyses were conducted. Results: The strategy ‘delayed MR-HIFU’ costs €706 more than EBRT, whilst ‘early MR-HIFU’ costs €1,875 more than EBRT.‘Early MR-HIFU’ adds 0,15 more QALYs than EBRT, resulting in an ICER of €12.755 per QALY and an incremental net monetary benefit of €8,631. At a threshold of 80,000€ per QALY there is a 77% probability that ‘early MR-HIFU’ is the most cost-effective option. Conclusion: Although there are still uncertainties relating to implementation of MR-HIFU in patient care, our modelling study shows that offering MR-HIFU as an early treatment would be the most cost-effective option in the Netherlands.


  • Open Access

    Patient Education and Communication in Palliative Radiotherapy: A Narrative Review

    by Erika Galietta, Costanza M. Donati, Filippo Mammini, Arina A. Zamfir, Alberto Bazzocchi, Rebecca Sassi, Renée Hovenier, Clemens Bos, Milly Buwenge, Silvia Cammelli, et al.

    Palliative radiotherapy (PRT) is central to symptom control in advanced cancer, yet referrals are often late, and patients and clinicians frequently hold misconceptions about intent, benefits, and logistics. Patient education may address these gaps, but the PRT-specific evidence base has not been consolidated. We conducted a narrative review following SANRA guidance. We searched PubMed, Scopus, and the Cochrane Library for English-language studies from 1 January 2000 to 18 July 2025. Eligible articles evaluated structured patient-education interventions or characterized education or communication content, information needs, or decision processes among adults referred to or receiving PRT. Two reviewers independently screened and extracted data. Owing to heterogeneity of designs and endpoints, we performed a narrative synthesis without meta-analysis. Six studies met criteria: two randomized controlled trials, two prospective pre–post studies, one qualitative interview study, and one observational communication study, conducted in the Netherlands, the United States, Canada, and Hong Kong. Education at referral or consultation improved knowledge, reduced decisional uncertainty, and increased readiness to proceed with PRT. Education integrated with treatment improved symptom outcomes, including higher rates of pain control at 12 weeks and faster time to pain control when a nurse-led pain-education program accompanied PRT for painful bone metastases, and improvements in dyspnea, fatigue, anxiety, and function in advanced lung cancer. Observational and qualitative work showed low patient question-asking and persistent curative expectations; overall quality of life generally did not change. Although the evidence is limited and heterogeneous, targeted, standardized education appears to improve decision quality and selected symptoms in PRT pathways. Pragmatic multi-site trials and implementation studies are needed to define content, timing, personnel, and delivery models that are scalable in routine care.

  • Open Access

    Impact of Pain Education on Pain Relief in Oncological Patients: A Narrative Review of Systematic Reviews and Meta-Analyses

    by Erika Galietta, Costanza M. Donati, Alberto Bazzocchi, Rebecca Sassi, Arina A. Zamfir, Renée Hovenier, Clemens Bos, Nikki Hendriks, Martijn F. Boomsma, Mira Huhtala, et al.

    Pain is a complex and burdensome symptom frequently experienced by oncological patients. Despite increased attention from healthcare providers and novel approaches, pain remains undertreated and prevalent in this patient population. Programs of patient education about pain (pain education, PE) have been proposed as a potential method to enhance pain management. However, the effectiveness of such programs and their impact on pain relief have shown variable results across studies. In this narrative review, we analyzed existing systematic reviews and meta-analyses on PE in oncological patients. A comprehensive literature search was conducted using PubMed, Scopus, and the Cochrane Library databases, following established guidelines. Studies meeting the selection criteria were selected and analyzed to evaluate the effectiveness of PE interventions. A total of nine publications, comprising six systematic reviews and three meta-analyses, were included. Across various clinical settings (inpatient and outpatient), the impact of pain education (PE) on pain intensity showed considerable variability: some reviews reported significant reductions, while others observed minimal or no effects. In contrast, PE consistently improved patients’ knowledge about pain and adherence to medication. However, the available evidence did not demonstrate significant improvements in quality of life. The observed heterogeneity in the results of pain relief outcomes could be attributed to the various types of pain analyzed and the diversity of clinical settings evaluated. Furthermore, differences in study designs, comprising the inclusion of non-randomized studies, contributed to the variability in findings. It remains unclear whether the effectiveness of PE is solely attributed to the educational content or if the attention provided to patients during the intervention partly explains the effect.


  • Trident: Three-dimensional ray tracing for modeling high intensity focused ultrasound ablation

    by Boris J. T. Breuer, Dragan Bošnački, Weizhou Xing, Beatrice Lena, Clemens Bos, Lambertus W. Bartels, Aaldert Elevelt, Daniela Modena, Peter A. J. Hilbers, Huub M. M. Ten Eikelder

    The lack of magnetic resonance (MR)–based thermometry in fat and bone poses significant challenges for temperature control in high intensity focused ultrasound (HIFU) ablation treatment. This paper introduces Trident, a ray tracing method to calculate the spatial heat production during HIFU, handling both longitudinal and shear waves in isotropic solids. Trident is especially advantageous for setups with complex geometries where other numerical methods prove computationally prohibitive. It outperforms current state-of-the-art ray tracing techniques by being at least 20 times faster without sacrificing accuracy. Conversely, when given the same running time, it can achieve 2 orders of magnitude higher accuracy. The improvement is due to the specially developed approach that captures the intensity decrease due to geometrical spreading in an efficient way. Trident was validated against a known reference method and temperature measurements on bovine cortical bone during HIFU sonication. Results indicate a good agreement with experimental temperature measurements. In highly attenuating solid cortical bone, the Trident method was able to model temperature increases within 3 K of peak temperatures measured by optical probes.


  • Open Access

    Eligibility for Magnetic Resonance‐Guided High Intensity Focused Ultrasound in Patients Referred for Radiotherapy on Painful Nonspinal Bone Metastases

    by Renée Hovenier, Derk J. Slotman, Chiara Gasperini, Alice Zamagni, Mira Huhtala, Manon N. G. J. A. Braat, Wietse S. C. Eppinga, Nicolien Kasperts, Erik C. J. Phernambucq, Martijn F. Boomsma, et al.

    Purpose: This prospective observational study aims to investigate which proportion of patients with bone metastases referred for External Beam Radiation Therapy (EBRT) would be able to undergo Magnetic Resonance‐guided High Intensity Focused Ultrasound (MR‐HIFU) as alternative to EBRT, and to examine reasons for ineligibility. Materials and Methods: Adult patients with nonspinal bone metastases referred to four radiotherapy departments were included. Local, multidisciplinary teams assessed which patients would be eligible for MR‐HIFU. The main reason(s) for ineligibility were categorized as patient‐related or lesion‐related. A random subsample of 30 ineligible patients were analyzed in detail to identify all reasons of ineligibility. Results: Overall, 57 of 741 (8%) nonspinal bone lesions were eligible for MR‐HIFU as alternative to EBRT. In total, 153 lesions (21%) in 130 patients were ineligible because of patient‐related factors, including curative treatment intent for oligo‐metastatic disease (10%), and poor performance status (8%). Of the remaining 588 bone metastases in 526 patients, 531 lesions (470 patients) were ineligible because of lesion‐related factors, including ‘lesion too extensive/advanced’ (29%), ‘(impending) pathological fracture’ (15%), ‘no moderate/severe pain from target lesion’ (11%). Proportion of ineligibility varied between centers from 70% to 96%, which was mainly attributable to differences in patient‐related factors. Within the random subsample of 30 ineligible patients, 27 patients had multiple reasons for ineligibility. Conclusion: A small proportion of patients, referred for EBRT of bone metastases, would be eligible to undergo MR‐HIFU as alternative palliation option. Taken together, patients presenting with small, localized lesions in nonspinal regions, primarily seeking pain relief without additional treatment goals are the most promising candidates for this therapy. These factors could be used to triage patients eligible for MR‐HIFU, thereby reducing unnecessary screening efforts, enhancing patient selection, and ultimately improve patient management strategies by optimizing the use of MR‐HIFU as a treatment option.


  • Open Access

    Mechanical HIFU and immune checkpoint inhibition: toward clinical implementation

    by Vera Mekers, Mirjam de Visser, Karijn Suijkerbuijk, Clemens Bos, Chrit Moonen, Roel Deckers, Gosse Adema

    Objective: Immune checkpoint inhibition (ICI) has significantly advanced the field of immuno-oncology, yet not all patients benefit from this therapy. Combining ICI with other therapeutic modalities, including tumor ablation, is currently being explored as a method to enhance ICI efficacy. Mechanical High-Intensity Focused Ultrasound (M-HIFU) represents a promising tumor ablative therapy, inducing cavitation within the tumor, resulting in tumor cell destruction and the release of danger signals and tumor antigens, two key factors contributing to anti-tumor immune responses. Methods/Results: Preclinical studies on the impact of M-HIFU on the anti-tumor immune response are guiding the translational application of this technique in the clinical setting. This review provides a comprehensive overview of the current understanding of the effects of M-HIFU on the immune system. We report on the effect of M-HIFU on soluble immune modulators and immune cells in different preclinical models, and potential contributions to the anti-tumor immune response. We discuss clinical studies applying M-HIFU and studies that have combined ICI with other ablative therapies to draw parallels to clinical implementation of M-HIFU. Further, we will highlight essential questions that should be addressed in future clinical trials exploring the combination of M-HIFU and ICI in the clinical setting. Conclusion: Overall, this review offers guidance for the clinical implementation of combining M-HIFU with ICI and highlights key questions that remain to be addressed in first clinical studies.


  • Open Access

    Factors Influencing the Adoption of Magnetic Resonance-Guided High-Intensity Focused Ultrasound for Painful Bone Metastases in Europe, A Group Concept Mapping Study

    by Julia Simões Corrêa Galendi, Ann-Cathrine Siefen, Debora M. Moretti, Sin Yuin Yeo, Holger Grüll, Grischa Bratke, Alessio Giuseppe Morganti, Alberto Bazzocchi, Chiara Gasperini, Francesca De Felice, et al.

    Magnetic resonance imaging-guided high-intensity focused ultrasound (MR-HIFU) is an innovative treatment for patients with painful bone metastases. The adoption of MR-HIFU will be influenced by several factors beyond its effectiveness. To identify contextual factors affecting the adoption of MR-HIFU, we conducted a group concept mapping (GCM) study in four European countries. The GCM was conducted in two phases. First, the participants brainstormed statements guided by the focus prompt “One factor that may influence the uptake of MR-HIFU in clinical practice is...”. Second, the participants sorted statements into categories and rated the statements according to their importance and changeability. To generate a concept map, multidimensional scaling and cluster analysis were conducted, and average ratings for each (cluster of) factors were calculated. Forty-five participants contributed to phase I and/or II (56% overall participation rate). The resulting concept map comprises 49 factors, organized in 12 clusters: “competitive treatments”, “physicians’ attitudes”, “alignment of resources”, “logistics and workflow”, “technical disadvantages”, “radiotherapy as first-line therapy”, “aggregating knowledge and improving awareness”, “clinical effectiveness”, “patients’ preferences”, “reimbursement”, “cost-effectiveness” and “hospital costs”. The factors identified echo those from the literature, but their relevance and interrelationship are case-specific. Besides evidence on clinical effectiveness, contextual factors from 10 other clusters should be addressed to support adoption of MR-HIFU.


  • Open Access

    Arterial spin labeling using spatio‐temporal encoding readout for robust perfusion imaging in inhomogenous magnetic fields

    by Suzanne L. Franklin, Megan Schuurmans, Martins Otikovs, Pim T. S. Borman, Matthias J. P. van Osch, Clemens Bos

    Purpose: To evaluate the feasibility of spatio‐temporal encoding (SPEN) readout for pseudo‐continuous ASL (pCASL) in brain, and its robustness to susceptibility artifacts as introduced by aneurysm clips.Methods: A 2D self‐refocused T2*‐compensated hybrid SPEN scheme, with super‐resolution reconstruction was implemented on a 1.5T Philips system.Q(=BWchirp*Tchirp) was varied and, the aneurysm clip‐induced artifact was evaluated in phantom (label‐images) as well as in vivo (perfusion‐weighted signal (PWS)‐maps and temporal SNR (tSNR)). In vivo results were compared to gradient‐echo EPI (GE‐EPI) and spin‐echo EPI (SE‐EPI). The dependence of tSNR on TR was evaluated separately for SPEN and SE‐EPI. SPEN withQ ˜ 75 encodes with the same off‐resonance robustness as EPI.Results: The clip‐induced artifact with SPEN decreased with increase in Q, and was smaller compared to SE‐EPI and GE‐EPI in vivo. tSNR decreased with Q and the tSNR of GE‐EPI and SE‐EPI corresponded to SPEN with a Q‐value of approximately ˜85 and ˜108, respectively. In addition, SPEN perfusion images showed a higher tSNR (p < 0.05) for TR = 4000 ms compared to TR = 2100 ms, while SE‐EPI did not. tSNR remained relatively stable when the time between SPEN‐excitation and start of the next labeling‐module was more than ˜1000 ms.Conclusion: Feasibility of combining SPEN with pCASL imaging was demonstrated, enabling cerebral perfusion measurements with a higher robustness to field inhomogeneity (Q > 75) compared to SE‐EPI and GE‐EPI. However, the SPEN chirp‐pulse saturates incoming blood, thereby reducing pCASL labeling efficiency of the next acquisition for short TRs. Future developments are needed to enable 3D scanning.